<DOC>
	<DOCNO>NCT02209792</DOCNO>
	<brief_summary>The primary objective extension study obtain long-term safety data BIRB 796 BS patient moderate severe Crohn 's disease 26 week treatment . Secondary objective evaluation efficacy BIRB 796 BS induce clinical remission response 26 week treatment .</brief_summary>
	<brief_title>Dose Finding Study BIRB 796 BS Patients With Moderate Severe Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Male female patient 18 65 year age Provision write informed consent accordance Good Clinical Practice local legislation prior study procedure Diagnosis Crohn 's disease document least 6 month . Preferably , inflammatory activity bowel confirm endoscopy within last 3 month Moderate severe Crohn 's disease , CDAI ≥220 ≤450 , baseline ( visit 2 ) Any follow therapy , provide respective criterion dosage , duration stability satisfy : Prednisone systemic corticosteroid least 12 week stable oral dosage ≤25 mg/d equivalent least two week prior visit 2 Budesonide stable dose ≤ 9 mg/d least 2 week prior visit 2 ( change amendment 1 , date 16 January 2002 ) 5Aminosalicylic Acid drugs/derivatives , provide give 3 month dosage stable least 4 week prior visit 2 6Mercaptopurine azathioprine , provide take 6 month dosage stable least 12 week prior visit 2 Methotrexate , provide take 6 month dosage stable ≤25 mg per week least 12 week prior visit 2 The following patient include 18week treatment extension : Patients receive BIRB 796 BS 8 week reach : Clinical remission ( define CDAI &lt; 150 ) 8 week Clinical response ( reduction CDAI ≥70 ) 8 week Patients willing continue treatment Pregnancy ( exclude visit 2 urine βhuman choriongonadotropintest woman childbearing potential ) breast feed Female patient childbearing potential ( 6 month postmenopausal surgically sterilise ) use approve form birth control ( hormonal contraceptive orally depot , intrauterine device ) Patients without sign inflammation bowel initial colonoscopy substudy Patients colostomy ileostomy Planned need surgery conduct trial due Crohn 's disease active gastrointestinal bleeding , peritonitis , intestinal obstruction , intraabdominal pancreatic abscess require surgical drainage Known suggest severe fix symptomatic stenosis small large intestine Severe underlie disease particular GI tract ( e.g . irritable bowel syndrome , celiac disease , infectious colitis ) Patients pathogens Clostridium difficile toxin detect stool culture screen period Other infectious , ischemic , immunological disease gastrointestinal involvement Patients short bowel syndrome Patients treatment failure tumor necrosis factor ( TNF ) block agent . Treatment failure define achieve clinical response ( improvement ≥70 point CDAI within 4 week ) clinical trial clinical practice discontinuation TNFblocking agent due ineffectiveness ( change accord amendment 1 , date 16 January 2002 ) Treatment cyclosporine A within 12 week prior visit 2 Last dose give within specified time period visit 2 follow compound : infliximab ( Remicade® ) : 8 week , investigational agent : 4 week 5 halflives , whichever longer Treatment antiinflammatory medication deviate criterion dosage , stability provide inclusion criterion Patients treat follow therapy : antibiotic provide dosage stable within 2 week prior visit 2 ; parenteral elemental diet ; intrarectal therapy Crohn 's disease 2 week prior visit 2 ( add amendment 1 , date 16 January 2002 ) Treatment : Nonsteroidal antiinflammatory drug ( NSAIDs ) within 2 week prior visit 2 ; Acetylsalicylic acid &gt; 100 mg/d ; Paracetamol ( acetaminophen ) &gt; 3 g/day ; Drug classify proton pump inhibitor : 7 day prior visit 2 . This exclusion criterion delete amendment 2 date 11 June 2002 . Drug classify H2receptorblocker antacid : 2 day prior visit 2 . This exclusion criterion delete amendment 2 date 11 June 2002 . Active infection serious infectious disease result hospitalisation require systemic antiinfective therapy within 4 week visit 2 Serologic evidence active hepatitis B and/or C Known HIVinfection History prior tuberculosis infection suspicion active infection screen base chest Xray do within 6 month prior treatment phase History cardiovascular , renal , neurologic , psychiatric , liver , immunologic , endocrine dysfunction clinically significant . A clinically significant disease define one , opinion investigator , may either put patient risk participation study disease may influence result study patient 's ability participate study Recent history heart failure ( one year less ) myocardial infarction patient cardiac arrhythmia require drug therapy ( change amendment 1 , date 16 January 2002 ) ECG result outside reference range clinical relevance include , limited QTcB &gt; 480 msec , PR interval &gt; 240 msec , QRS interval &gt; 110 msec History malignant disease last 5 year suspicion active malignant disease except successfully treat squamous basal cell carcinoma skin except patient cervical carcinoma situ adequate treatment follow Clinically significant abnormal baseline haematology , blood chemistry urinalysis abnormality define disease list exclusion criterion Any follow specific laboratory abnormality visit 1 : alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) great upper limit normal range ( ULN ) Total bilirubin great ULN except patient document Gilbert 's disease Gammaglutamyltransferase , alkaline phosphatase lactate dehydrogenase great 1.5 x ULN White blood cell count great 1.5 ULN due Crohn 's disease assess investigator Serum creatinine 1.5 x ULN History drug alcohol abuse within past two year active drug alcohol abuse Participation another clinical trial within 4 week 5 halflives respective investigational agent , whichever long Hypersensitivity trial drug Inability comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>